EZH2 mutations are frequent and represent an early event in follicular lymphoma.

Csaba Bödör, Vera Grossmann, Nikolay Popov, Jessica Okosun, Ciarán O'Riain, King Tan, Jacek Marzec, Shamzah Araf, Jun Wang, Abigail M. Lee, Andrew Clear, Silvia Montoto, Janet Matthews, Sameena Iqbal, Hajnalka Rajnai, Andreas Rosenwald, German Ott, Elias Campo, Lisa Rimsza, Erlend B. SmelandWing C. Chan, Rita M. Braziel, Louis M. Staudt, George Wright, T. Andrew Lister, Olivier Elemento, Robert Hills, John G. Gribben, Claude Chelala, András Matolcsy, Alexander Kohlmann, Torsten Haferlach, Randy D. Gascoyne, Jude Fitzgibbon

Research output: Contribution to journalArticle

117 Citations (Scopus)

Abstract

Gain of function mutations in the H3K27 methyltransferase EZH2 represent a promising therapeutic target in germinal center lymphomas. In this study, we assessed the frequency and distribution of EZH2 mutations in a large cohort of patients with follicular lymphoma (FL) (n = 366) and performed a longitudinal analysis of mutation during the disease progression from FL to transformed FL (tFL) (n = 33). Mutations were detected at 3 recurrent mutation hot spots (Y646, A682, and A692) in 27% of FL cases with variant allele frequencies (VAF) ranging from 2% to 61%. By comparing VAF of EZH2 with other mutation targets (CREBBP, MLL2, TNFRSF14, and MEF2B), we were able to distinguish patients harboring clonal EZH2 mutation from rarer cases with subclonal mutations. Overall, the high incidence of EZH2 mutations in FL and their stability during disease progression makes FL an appropriate disease to evaluate EZH2 targeted therapy.

Original languageEnglish (US)
Pages (from-to)3165-3168
Number of pages4
JournalBlood
Volume122
Issue number18
StatePublished - Oct 31 2013
Externally publishedYes

Fingerprint

Follicular Lymphoma
Mutation
Methyltransferases
Gene Frequency
Disease Progression
Germinal Center
Lymphoma
Incidence

ASJC Scopus subject areas

  • Hematology
  • Biochemistry
  • Cell Biology
  • Immunology
  • Medicine(all)

Cite this

Bödör, C., Grossmann, V., Popov, N., Okosun, J., O'Riain, C., Tan, K., ... Fitzgibbon, J. (2013). EZH2 mutations are frequent and represent an early event in follicular lymphoma. Blood, 122(18), 3165-3168.

EZH2 mutations are frequent and represent an early event in follicular lymphoma. / Bödör, Csaba; Grossmann, Vera; Popov, Nikolay; Okosun, Jessica; O'Riain, Ciarán; Tan, King; Marzec, Jacek; Araf, Shamzah; Wang, Jun; Lee, Abigail M.; Clear, Andrew; Montoto, Silvia; Matthews, Janet; Iqbal, Sameena; Rajnai, Hajnalka; Rosenwald, Andreas; Ott, German; Campo, Elias; Rimsza, Lisa; Smeland, Erlend B.; Chan, Wing C.; Braziel, Rita M.; Staudt, Louis M.; Wright, George; Lister, T. Andrew; Elemento, Olivier; Hills, Robert; Gribben, John G.; Chelala, Claude; Matolcsy, András; Kohlmann, Alexander; Haferlach, Torsten; Gascoyne, Randy D.; Fitzgibbon, Jude.

In: Blood, Vol. 122, No. 18, 31.10.2013, p. 3165-3168.

Research output: Contribution to journalArticle

Bödör, C, Grossmann, V, Popov, N, Okosun, J, O'Riain, C, Tan, K, Marzec, J, Araf, S, Wang, J, Lee, AM, Clear, A, Montoto, S, Matthews, J, Iqbal, S, Rajnai, H, Rosenwald, A, Ott, G, Campo, E, Rimsza, L, Smeland, EB, Chan, WC, Braziel, RM, Staudt, LM, Wright, G, Lister, TA, Elemento, O, Hills, R, Gribben, JG, Chelala, C, Matolcsy, A, Kohlmann, A, Haferlach, T, Gascoyne, RD & Fitzgibbon, J 2013, 'EZH2 mutations are frequent and represent an early event in follicular lymphoma.', Blood, vol. 122, no. 18, pp. 3165-3168.
Bödör C, Grossmann V, Popov N, Okosun J, O'Riain C, Tan K et al. EZH2 mutations are frequent and represent an early event in follicular lymphoma. Blood. 2013 Oct 31;122(18):3165-3168.
Bödör, Csaba ; Grossmann, Vera ; Popov, Nikolay ; Okosun, Jessica ; O'Riain, Ciarán ; Tan, King ; Marzec, Jacek ; Araf, Shamzah ; Wang, Jun ; Lee, Abigail M. ; Clear, Andrew ; Montoto, Silvia ; Matthews, Janet ; Iqbal, Sameena ; Rajnai, Hajnalka ; Rosenwald, Andreas ; Ott, German ; Campo, Elias ; Rimsza, Lisa ; Smeland, Erlend B. ; Chan, Wing C. ; Braziel, Rita M. ; Staudt, Louis M. ; Wright, George ; Lister, T. Andrew ; Elemento, Olivier ; Hills, Robert ; Gribben, John G. ; Chelala, Claude ; Matolcsy, András ; Kohlmann, Alexander ; Haferlach, Torsten ; Gascoyne, Randy D. ; Fitzgibbon, Jude. / EZH2 mutations are frequent and represent an early event in follicular lymphoma. In: Blood. 2013 ; Vol. 122, No. 18. pp. 3165-3168.
@article{8d26b6e1d6a0442d88682355e6ec047e,
title = "EZH2 mutations are frequent and represent an early event in follicular lymphoma.",
abstract = "Gain of function mutations in the H3K27 methyltransferase EZH2 represent a promising therapeutic target in germinal center lymphomas. In this study, we assessed the frequency and distribution of EZH2 mutations in a large cohort of patients with follicular lymphoma (FL) (n = 366) and performed a longitudinal analysis of mutation during the disease progression from FL to transformed FL (tFL) (n = 33). Mutations were detected at 3 recurrent mutation hot spots (Y646, A682, and A692) in 27{\%} of FL cases with variant allele frequencies (VAF) ranging from 2{\%} to 61{\%}. By comparing VAF of EZH2 with other mutation targets (CREBBP, MLL2, TNFRSF14, and MEF2B), we were able to distinguish patients harboring clonal EZH2 mutation from rarer cases with subclonal mutations. Overall, the high incidence of EZH2 mutations in FL and their stability during disease progression makes FL an appropriate disease to evaluate EZH2 targeted therapy.",
author = "Csaba B{\"o}d{\"o}r and Vera Grossmann and Nikolay Popov and Jessica Okosun and Ciar{\'a}n O'Riain and King Tan and Jacek Marzec and Shamzah Araf and Jun Wang and Lee, {Abigail M.} and Andrew Clear and Silvia Montoto and Janet Matthews and Sameena Iqbal and Hajnalka Rajnai and Andreas Rosenwald and German Ott and Elias Campo and Lisa Rimsza and Smeland, {Erlend B.} and Chan, {Wing C.} and Braziel, {Rita M.} and Staudt, {Louis M.} and George Wright and Lister, {T. Andrew} and Olivier Elemento and Robert Hills and Gribben, {John G.} and Claude Chelala and Andr{\'a}s Matolcsy and Alexander Kohlmann and Torsten Haferlach and Gascoyne, {Randy D.} and Jude Fitzgibbon",
year = "2013",
month = "10",
day = "31",
language = "English (US)",
volume = "122",
pages = "3165--3168",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "18",

}

TY - JOUR

T1 - EZH2 mutations are frequent and represent an early event in follicular lymphoma.

AU - Bödör, Csaba

AU - Grossmann, Vera

AU - Popov, Nikolay

AU - Okosun, Jessica

AU - O'Riain, Ciarán

AU - Tan, King

AU - Marzec, Jacek

AU - Araf, Shamzah

AU - Wang, Jun

AU - Lee, Abigail M.

AU - Clear, Andrew

AU - Montoto, Silvia

AU - Matthews, Janet

AU - Iqbal, Sameena

AU - Rajnai, Hajnalka

AU - Rosenwald, Andreas

AU - Ott, German

AU - Campo, Elias

AU - Rimsza, Lisa

AU - Smeland, Erlend B.

AU - Chan, Wing C.

AU - Braziel, Rita M.

AU - Staudt, Louis M.

AU - Wright, George

AU - Lister, T. Andrew

AU - Elemento, Olivier

AU - Hills, Robert

AU - Gribben, John G.

AU - Chelala, Claude

AU - Matolcsy, András

AU - Kohlmann, Alexander

AU - Haferlach, Torsten

AU - Gascoyne, Randy D.

AU - Fitzgibbon, Jude

PY - 2013/10/31

Y1 - 2013/10/31

N2 - Gain of function mutations in the H3K27 methyltransferase EZH2 represent a promising therapeutic target in germinal center lymphomas. In this study, we assessed the frequency and distribution of EZH2 mutations in a large cohort of patients with follicular lymphoma (FL) (n = 366) and performed a longitudinal analysis of mutation during the disease progression from FL to transformed FL (tFL) (n = 33). Mutations were detected at 3 recurrent mutation hot spots (Y646, A682, and A692) in 27% of FL cases with variant allele frequencies (VAF) ranging from 2% to 61%. By comparing VAF of EZH2 with other mutation targets (CREBBP, MLL2, TNFRSF14, and MEF2B), we were able to distinguish patients harboring clonal EZH2 mutation from rarer cases with subclonal mutations. Overall, the high incidence of EZH2 mutations in FL and their stability during disease progression makes FL an appropriate disease to evaluate EZH2 targeted therapy.

AB - Gain of function mutations in the H3K27 methyltransferase EZH2 represent a promising therapeutic target in germinal center lymphomas. In this study, we assessed the frequency and distribution of EZH2 mutations in a large cohort of patients with follicular lymphoma (FL) (n = 366) and performed a longitudinal analysis of mutation during the disease progression from FL to transformed FL (tFL) (n = 33). Mutations were detected at 3 recurrent mutation hot spots (Y646, A682, and A692) in 27% of FL cases with variant allele frequencies (VAF) ranging from 2% to 61%. By comparing VAF of EZH2 with other mutation targets (CREBBP, MLL2, TNFRSF14, and MEF2B), we were able to distinguish patients harboring clonal EZH2 mutation from rarer cases with subclonal mutations. Overall, the high incidence of EZH2 mutations in FL and their stability during disease progression makes FL an appropriate disease to evaluate EZH2 targeted therapy.

UR - http://www.scopus.com/inward/record.url?scp=84891603187&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84891603187&partnerID=8YFLogxK

M3 - Article

C2 - 24052547

AN - SCOPUS:84891603187

VL - 122

SP - 3165

EP - 3168

JO - Blood

JF - Blood

SN - 0006-4971

IS - 18

ER -